The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised us and the Ozempic Medicine Shortage Action Group (MSAG) that supply will continue to be limited until 31 December 2025.
Ozempic is a semaglutide product approved for the management of type 2 diabetes not adequately managed by other medications, in conjunction with diet and exercise.
A separate semaglutide product, Wegovy, is approved to assist with chronic weight management.
We consulted health professionals and patient groups represented on the MSAG. The updated advice of the action group to health professionals is to:
consider the ongoing shortage when prescribing Ozempic, inform patients that supply is expected to be limited in 2025 and discuss alternative treatments when patients are unable to access the medicine
prescribe and supply both Ozempic and Wegovy according to their approved indications.
Novo Nordisk advised that they are continuing to increase manufacturing capacity, but it would take time to build supply levels to meet global and local demand.
